Minimum Stada Takeover Level Reached Just In Time By Bain And Cinven
Executive Summary
A last-minute surge in shareholder acceptances has pushed Bain and Cinven's €5.4bn takeover offer for Stada Arzneimittel over the finish line just in time.
You may also be interested in...
Bain and Cinven Bow To Elliott Pressure Over Stada Price
The private equity firms have agreed to pay more to Stada minority stockholders in a settlement that could add an extra €180-190m to their initial €5.4bn purchase price.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.